Biomarkers /
FLT3
Overview
FLT3 (fms-related tyrosine kinase 3) encodes for the receptor-type tyrosine-protein kinase FLT3. FLT3 activates pathways in hematopoietic cells (Gene 2013). FLT3 is frequently mutated in acute myeloid leukemia, other hematologic malignancies, and colorectal cancer (COSMIC).
FLT3 is altered in 2.79% of all cancers with acute myeloid leukemia, colon adenocarcinoma, lung adenocarcinoma, cutaneous melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in FLT3 are FLT3 Mutation (2.20%), FLT3 Exon 14 Mutation (0.47%), FLT3 Amplification (0.49%), FLT3 D7G (14.38%), and FLT3 Exon 20 Mutation (0.23%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of FLT3 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.